HRP20201147T1 - (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors - Google Patents

(2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors Download PDF

Info

Publication number
HRP20201147T1
HRP20201147T1 HRP20201147TT HRP20201147T HRP20201147T1 HR P20201147 T1 HRP20201147 T1 HR P20201147T1 HR P20201147T T HRP20201147T T HR P20201147TT HR P20201147 T HRP20201147 T HR P20201147T HR P20201147 T1 HRP20201147 T1 HR P20201147T1
Authority
HR
Croatia
Prior art keywords
compound
formula
rhinitis
asthma
induced
Prior art date
Application number
HRP20201147TT
Other languages
Croatian (hr)
Inventor
Hans Roland Lönn
Stephen Connolly
Steven Swallow
Staffan PO KARLSSON
Carl-Johan Aurell
John Fritiof PONTÉN
Kevin James Doyle
Amanda Jane Van De Poël
Graham Peter Jones
David Wyn Watson
Jacqueline Anne Macritchie
Nicholas John Palmer
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52432834&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20201147(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HRP20201147T1 publication Critical patent/HRP20201147T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Claims (7)

1. Spoj formule (I) [image] gdje R1 je [image] X je izabran od O, S ili CF2; R6 je izabran od C1-3alkila, pri čemu je navedeni C1-3alkil izborno supstituiran sa 1, 2 ili 3 F; R7 je izabran od vodika, F, Cl ili CH3; ili njegova farmaceutski prihvatljiva sol.1. Compound of formula (I) [image] where R1 is [image] X is selected from O, S or CF2; R 6 is selected from C 1-3 alkyl, wherein said C 1-3 alkyl is optionally substituted with 1, 2 or 3 F; R 7 is selected from hydrogen, F, Cl or CH 3 ; or a pharmaceutically acceptable salt thereof. 2. Farmaceutska kompozicija koja sadrži spoj formule (I) prema patentnom zahtjevu 1 i farmaceutski prihvatljiv adjuvans, razblaživač ili nosač.2. A pharmaceutical composition containing a compound of formula (I) according to patent claim 1 and a pharmaceutically acceptable adjuvant, diluent or carrier. 3. Spoj formule (I) prema patentnom zahtjevu 1 za upotrebu u terapiji.3. Compound of formula (I) according to patent claim 1 for use in therapy. 4. Spoj formule (I) prema patentnom zahtjevu 1, za upotrebu u liječenju opstruktivnih bolesti dišnih puteva: uključujući bilo koju od astme, uključujući bronhijalnu, alergijsku, intrinzičnu, ekstrinzičnu, induciranu vježbanjem, induciranu lijekom (uključujući induciranu aspirinom i sa NSAID) i astmu induciranu prašinom, intermitetnu i perzistentnu i svih težina, i druge uzroke hiper-responsivnosti dišnih puteva; kroničnu opstruktivnu bolest pluća (COPD); bronhitis, uključujući infektivni i eozinofilni bronhitis; emfizem; bronhiektazu; cističnu fibrozu; sarkoidozu; deficijenciju alfa-1 antitripsina; pluća farmera i srodne bolesti; hipersenzitivni pneumonitis; fibrozu pluća, uključujući kriptogeni fibrozni alveolitis, idiopatske intersticijalne pneumonije, fibrozu koju komplicira anti-neoplastična terapija i kronična infekcija, uključujući tuberkulozu i aspergilozu i druge gljivične infekcije; komplikacije transplantacije pluća; vaskulitis i trombotičke poremećaje vaskulature pluća, i plućnu hipertenziju; antitusivnu aktivnost uključujući tretman kroničnog kašlja povezanog sa inflamatornim i sekretornim stanjima dišnih puteva, i jatrogeni kašalj; akutni i kronični rinitis uključujući rinitis medikamentozu, i vazomotorni rinitis; alergijski rinitis od višegodišnjih i sezonskih biljaka uključujući rinitis nervozu (peludnu groznicu); nazalnu polipozu; akutnu virusnu infekciju uključujući običnu prehladu, i infekciju kao posljedicu respiratornog sincicijalnog virusa, influencu, koronavirus (uključujući SARS) i adenovirus, akutnu ozljedu pluća, adultni respiratorni distres sindrom (ARDS), kao i pogoršanja svakog od gore navedenih stanja bolesti respiratornog trakta, naročito pogoršanja svih tipova astme ili COPD.4. A compound of formula (I) according to claim 1, for use in the treatment of obstructive airway diseases: including any of asthma, including bronchial, allergic, intrinsic, extrinsic, exercise-induced, drug-induced (including aspirin and NSAID-induced) and dust-induced asthma, intermittent and persistent and of all severity, and other causes of airway hyper-responsiveness; chronic obstructive pulmonary disease (COPD); bronchitis, including infectious and eosinophilic bronchitis; emphysema; bronchiectasis; cystic fibrosis; sarcoidosis; alpha-1 antitrypsin deficiency; farmer's lung and related diseases; hypersensitivity pneumonitis; pulmonary fibrosis, including cryptogenic fibrous alveolitis, idiopathic interstitial pneumonias, fibrosis complicated by anti-neoplastic therapy and chronic infection, including tuberculosis and aspergillosis and other fungal infections; complications of lung transplantation; vasculitis and thrombotic disorders of the lung vasculature, and pulmonary hypertension; antitussive activity including the treatment of chronic cough associated with inflammatory and secretory conditions of the airways, and iatrogenic cough; acute and chronic rhinitis, including rhinitis medicamentosa, and vasomotor rhinitis; allergic rhinitis from perennial and seasonal plants including rhinitis nervosa (hay fever); nasal polyposis; acute viral infection including the common cold, and infection as a result of respiratory syncytial virus, influenza, coronavirus (including SARS) and adenovirus, acute lung injury, adult respiratory distress syndrome (ARDS), as well as exacerbations of any of the above-mentioned respiratory tract disease conditions, especially exacerbations of all types of asthma or COPD. 5. Spoj formule (I) za upotrebu prema patentnom zahtjevu 4 za upotrebu u liječenju astme ili kronične opstruktivne bolesti pluća.5. A compound of formula (I) for use according to claim 4 for use in the treatment of asthma or chronic obstructive pulmonary disease. 6. Spoj formule (I) za upotrebu prema patentnom zahtjevu 4 za upotrebu u liječenju bronhiektaze.6. A compound of formula (I) for use according to claim 4 for use in the treatment of bronchiectasis. 7. Kombinacija spoja formule (I) prema patentnom zahtjevu 1 i jednog ili više sredstava nezavisno izabranih od: • nesteroidnog agonista receptora glukokoritokoida; • selektivnog agonista β2 adrenoceptora; • inhibitora fosfodiesteraze; • inhibitora proteaze; • glukokortikoida; • antiholinergičkog sredstva; • modulatora funkcije receptora za hemokin; i • inhibitora funkcije kinaze.7. Combination of the compound of formula (I) according to claim 1 and one or more agents independently selected from: • non-steroidal glucocorticoid receptor agonist; • selective β2 adrenoceptor agonist; • phosphodiesterase inhibitors; • protease inhibitors; • glucocorticoids; • anticholinergic agent; • modulator of chemokine receptor function; and • inhibitors of kinase function.
HRP20201147TT 2014-01-24 2020-07-23 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors HRP20201147T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461931090P 2014-01-24 2014-01-24
EP17195612.1A EP3323814B1 (en) 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors

Publications (1)

Publication Number Publication Date
HRP20201147T1 true HRP20201147T1 (en) 2020-12-11

Family

ID=52432834

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20180116TT HRP20180116T1 (en) 2014-01-24 2018-01-22 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors
HRP20201147TT HRP20201147T1 (en) 2014-01-24 2020-07-23 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20180116TT HRP20180116T1 (en) 2014-01-24 2018-01-22 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors

Country Status (37)

Country Link
US (16) US9522894B2 (en)
EP (3) EP3097086B1 (en)
JP (5) JP6469711B2 (en)
KR (1) KR102417684B1 (en)
CN (2) CN110483492B (en)
AP (1) AP2016009322A0 (en)
AR (1) AR099177A1 (en)
AU (4) AU2015208932C1 (en)
BR (1) BR112016016224B1 (en)
CA (1) CA2935625C (en)
CL (1) CL2016001889A1 (en)
CR (1) CR20160327A (en)
CY (2) CY1120049T1 (en)
DK (2) DK3323814T3 (en)
DO (1) DOP2016000175A (en)
EA (1) EA032794B1 (en)
ES (2) ES2808060T3 (en)
HK (2) HK1225730B (en)
HR (2) HRP20180116T1 (en)
HU (2) HUE038274T2 (en)
IL (3) IL246614B (en)
LT (2) LT3323814T (en)
MX (1) MX368840B (en)
MY (1) MY194850A (en)
NO (1) NO2699580T3 (en)
NZ (2) NZ722063A (en)
PE (1) PE20161218A1 (en)
PH (1) PH12016501439B1 (en)
PL (2) PL3097086T3 (en)
PT (2) PT3323814T (en)
RS (2) RS56919B1 (en)
SG (2) SG11201606052TA (en)
SI (2) SI3097086T1 (en)
TW (1) TWI690517B (en)
UY (1) UY35963A (en)
WO (1) WO2015110826A1 (en)
ZA (2) ZA201605856B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (en) 2014-01-24 2018-02-24
US20180028541A1 (en) * 2016-07-29 2018-02-01 Astrazeneca Ab Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors for treating bronchiectasis
AU2019217870A1 (en) * 2018-02-07 2020-08-27 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating ANCA associated vasculitides
EP3758708A1 (en) * 2018-03-01 2021-01-06 AstraZeneca AB Pharmaceutical compositions comprising (2s)--{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide
WO2020018551A1 (en) * 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)- n-[(1s)-1-cyano-2-phenylethyl]-1,4- oxazepane-2-carboxamides for treating inflammatory bowel disease
AU2019306532A1 (en) * 2018-07-17 2021-03-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating Lupus Nephritis
CN111689923B (en) * 2019-03-12 2022-11-08 中国科学院上海药物研究所 Cyclic lipopeptide compound with activity of reversing multidrug resistance of tumors, preparation method and application thereof
KR20210048431A (en) * 2019-10-23 2021-05-03 주식회사 종근당 Compositions for preventing or treating chronic obstructive pulmonary diseases(COPD)
CA3181285A1 (en) * 2020-07-20 2022-01-27 Jessica BASSO Methods for extracting neutrophil serine proteases and treating dipeptidyl peptidase 1-mediated conditions
CN115996923A (en) 2020-08-26 2023-04-21 四川海思科制药有限公司 Nitrile derivative as dipeptidyl peptidase 1 inhibitor and application thereof
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CN114159446A (en) * 2020-09-11 2022-03-11 中国科学院上海营养与健康研究所 Use of cathepsin C inhibitors for the treatment of tumor metastasis
KR20230117738A (en) 2020-12-04 2023-08-09 레이스톤 바이오파마 컴퍼니 리미티드 Small molecule inhibitors of cathepsin C and their medicinal uses
WO2022140516A1 (en) * 2020-12-22 2022-06-30 Insmed Incorporated Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
AU2022218443A1 (en) * 2021-02-05 2023-09-21 Medshine Discovery Inc. Fused ring derivatives containing 1,4-oxazepane
AU2022376535A1 (en) * 2021-10-29 2024-05-02 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis
WO2023134656A1 (en) * 2022-01-11 2023-07-20 上海壹典医药科技开发有限公司 Peptidyl nitrile compound and use thereof
WO2023159120A1 (en) * 2022-02-16 2023-08-24 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa
WO2023160542A1 (en) * 2022-02-22 2023-08-31 四川海思科制药有限公司 Salt and crystal form of dipeptidyl peptidase inhibitor compound
TW202333739A (en) * 2022-02-22 2023-09-01 大陸商四川海思科製藥有限公司 Dipeptidyl peptidase 1 inhibitor polymorph, preparation method and use therefor
WO2023160541A1 (en) * 2022-02-22 2023-08-31 四川海思科制药有限公司 Preparation method of nitrogen-containing heterocyclic compound
CN114644562B (en) * 2022-04-29 2023-08-22 常州大学 Organic small molecule fluorescent compound with red shift fluorescent emission, preparation method and application
WO2023236879A1 (en) * 2022-06-07 2023-12-14 瑞石生物医药有限公司 Polymorph of benzo[c]chroman compound, preparation method therefor and use thereof
WO2023236877A1 (en) * 2022-06-07 2023-12-14 瑞石生物医药有限公司 Pharmaceutically acceptable salt of benzo[c]chroman compound and polymorphic form and use of pharmaceutically acceptable salt
WO2024008680A1 (en) 2022-07-06 2024-01-11 Chiesi Farmaceutici S.P.A. Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors
WO2024081889A1 (en) 2022-10-14 2024-04-18 Genesis Therapeutics, Inc. 4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer
WO2024088307A1 (en) * 2022-10-26 2024-05-02 上海壹迪生物技术有限公司 Novel peptidyl nitrile compound and use thereof

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2782151B2 (en) 1993-07-16 1998-07-30 博 吉田 End stopper for shock absorbing fence
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6462076B2 (en) 2000-06-14 2002-10-08 Hoffmann-La Roche Inc. Beta-amino acid nitrile derivatives as cathepsin K inhibitors
DK1317555T3 (en) 2000-09-08 2008-03-25 Prozymex As Dipeptidyl peptidase in crystal structure and applications thereof
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
CN1315806C (en) 2001-12-04 2007-05-16 霍夫曼·拉罗奇有限公司 Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors
US20040253311A1 (en) 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
WO2004076434A1 (en) 2003-02-28 2004-09-10 Aic Dipeptidyl peptidase inhibitors
EP2258365B1 (en) 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
EP1975153A3 (en) 2003-05-30 2010-03-31 Prozymex A/S Protease inhibitors
EP1638925A1 (en) 2003-06-18 2006-03-29 Prozymex A/S Protease inhibitors
KR101504729B1 (en) 2004-04-07 2015-03-19 리나트 뉴로사이언스 코프. Pharmaceutical composotion for treating bone cancer pain by administering a nerve growth factor antagonist
US20070286854A1 (en) 2004-04-28 2007-12-13 Bayer Healthcare Ag Diagnostics And Therapeutics For Diseases Associated With Dipeptidyl-Peptidase 1 (Dpp1)
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
SE0401657D0 (en) 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
EA200971133A1 (en) 2004-06-29 2010-10-29 Никомед Данмарк Апс MANUFACTURING PHARMACEUTICAL COMPOSITIONS WITH QUICKLY FROZEN ON BASED WATER-SOLUBLE MEDICINES AND PHARMACEUTICAL COMPOSITIONS OBTAINED BY THE METHOD FOR INVENTION
US20090054358A1 (en) 2004-07-19 2009-02-26 The John Hopkins University Flt3 inhibitors for immune suppression
CA3054535A1 (en) 2005-02-18 2006-08-24 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
MX2007015679A (en) 2005-06-30 2008-02-21 Amgen Inc Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer.
EP2125816A2 (en) 2007-03-07 2009-12-02 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
WO2009026701A1 (en) 2007-08-29 2009-03-05 Methylgene Inc. Sirtuin inhibitors
BRPI0817311A2 (en) 2007-09-25 2015-03-17 Novartis Ag Treatment of lung diseases with aerosol medications such as vancomycin
EA201000958A1 (en) * 2007-12-12 2010-12-30 Астразенека Аб PEPTIDYLNITRILES AND THEIR APPLICATION AS DIPEPTIDYLPEPTIDASE I INHIBITORS
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
UY31867A (en) 2008-06-06 2010-01-29 Boehringer Ingelheim Int NEW SOLID PHARMACEUTICAL FORMULATIONS THAT INCLUDE BIBW 2992
RU2016116516A (en) 2008-12-08 2018-12-07 Мандифарма Интернэшнл Корпорейшн Лимитед COMPOSITIONS OF INHIBITORS OF TYROSINKINASE PROTEIN RECEPTORS
BRPI1016132B8 (en) 2009-04-01 2021-05-25 Bial Portela & Ca Sa composition, pharmaceutical formulation, process of obtaining a stable pharmaceutical formulation
AU2010244218B2 (en) 2009-05-07 2012-07-19 Astrazeneca Ab Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750
WO2010142985A1 (en) * 2009-06-10 2010-12-16 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
LT3150198T (en) 2010-04-07 2021-12-10 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
WO2011154677A1 (en) * 2010-06-09 2011-12-15 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
IT1404036B1 (en) 2010-12-17 2013-11-08 Oto Melara Spa ARMORED VEHICLE WITH IMPROVED STRUCTURE.
CN103491777B (en) 2011-02-11 2015-05-06 葛兰素史密斯克莱知识产权发展有限公司 Cathepsin c inhibitors
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
US8999975B2 (en) 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
ES2674451T3 (en) 2012-02-21 2018-06-29 Merck Patent Gmbh 8-substituted 2-amino- [1,2,4] triazolo [1,5-a] pyrazines as SYK tyrosine kinase inhibitors and GCN2 serine kinase inhibitors
JP6172143B2 (en) 2012-04-17 2017-08-02 アステラス製薬株式会社 Nitrogenous bicyclic aromatic heterocyclic compounds
WO2014091443A1 (en) 2012-12-13 2014-06-19 Glaxo Group Limited Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis
EP2775304A1 (en) 2013-03-07 2014-09-10 Universitätsspital Basel Methods for detecting inflammatory disorder
WO2014140091A1 (en) 2013-03-14 2014-09-18 Boehringer Ingelheim International Gmbh Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
NZ710034A (en) 2013-03-14 2020-06-26 Boehringer Ingelheim Int Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
EP2970228B1 (en) 2013-03-14 2017-05-10 Boehringer Ingelheim International GmbH Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano-methyl)-amides inhibitors of cathepsin c
EP2970230B1 (en) 2013-03-14 2019-05-22 Boehringer Ingelheim International GmbH Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
UY35400A (en) 2013-03-15 2014-10-31 Novartis Ag COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITARY DISEASES
MX2015013845A (en) 2013-04-01 2016-05-09 Pulmatrix Inc Tiotropium dry powders.
WO2015032945A1 (en) 2013-09-09 2015-03-12 Prozymex A/S Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
WO2015032942A1 (en) 2013-09-09 2015-03-12 Prozymex A/S N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
NO2699580T3 (en) 2014-01-24 2018-02-24
DK3466432T3 (en) 2014-05-15 2020-09-28 Insmed Inc PROCEDURES FOR THE TREATMENT OF PULMONAL NON-TUBERCULOSE MICOBACTERIAL INFECTIONS
US9625460B2 (en) 2014-05-30 2017-04-18 Versitech Limited Methods and compositions for use of neutrophil elastase and proteinase 3 as diagnostic biomarkers
JP6529575B2 (en) 2014-08-01 2019-06-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Substituted oxetanes and their use as inhibitors of cathepsin C
KR102510588B1 (en) 2014-09-12 2023-03-17 베링거 인겔하임 인터내셔날 게엠베하 Spirocyclic inhibitors of cathepsin c
CA2965566A1 (en) 2014-11-14 2016-05-19 Boehringer Ingelheim International Gmbh Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (sstr4) agonists
AU2016227618B2 (en) 2015-03-05 2020-06-04 Neuprozyme Therapeutics ApS Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors
US20180028541A1 (en) 2016-07-29 2018-02-01 Astrazeneca Ab Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors for treating bronchiectasis
AU2019217870A1 (en) 2018-02-07 2020-08-27 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating ANCA associated vasculitides
EP3758708A1 (en) 2018-03-01 2021-01-06 AstraZeneca AB Pharmaceutical compositions comprising (2s)--{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide
AU2019306532A1 (en) 2018-07-17 2021-03-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating Lupus Nephritis
WO2020018551A1 (en) 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)- n-[(1s)-1-cyano-2-phenylethyl]-1,4- oxazepane-2-carboxamides for treating inflammatory bowel disease
AU2020289560A1 (en) 2019-06-05 2021-12-23 Emory University Peptidomimetics for the treatment of coronavirus and picornavirus infections
WO2022140516A1 (en) 2020-12-22 2022-06-30 Insmed Incorporated Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
WO2022232420A1 (en) 2021-04-29 2022-11-03 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cancer
EP4329767A1 (en) 2021-04-29 2024-03-06 Insmed Incorporated Certain-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cystic fibrosis

Also Published As

Publication number Publication date
US11814359B2 (en) 2023-11-14
PL3097086T3 (en) 2018-04-30
RS60639B1 (en) 2020-09-30
CN105980367A (en) 2016-09-28
NZ722063A (en) 2017-09-29
RS56919B1 (en) 2018-05-31
PH12016501439A1 (en) 2017-02-06
AU2017200338B2 (en) 2018-03-01
US11655224B2 (en) 2023-05-23
US11655222B2 (en) 2023-05-23
US11673872B2 (en) 2023-06-13
JP2019070029A (en) 2019-05-09
UY35963A (en) 2015-07-31
EA201691375A1 (en) 2017-01-30
PT3097086T (en) 2018-02-21
US11773069B2 (en) 2023-10-03
SG11201606052TA (en) 2016-08-30
CY1120049T1 (en) 2018-12-12
SG10201701056QA (en) 2017-03-30
ZA201800431B (en) 2019-09-25
JP6804570B2 (en) 2020-12-23
JP6469711B2 (en) 2019-02-13
SI3097086T1 (en) 2018-04-30
ZA201605856B (en) 2020-02-26
JP2023156479A (en) 2023-10-24
HUE052421T2 (en) 2021-04-28
EP3097086B1 (en) 2017-12-13
NZ734768A (en) 2022-09-30
EP3097086A1 (en) 2016-11-30
AR099177A1 (en) 2016-07-06
US20230278969A1 (en) 2023-09-07
EP3323814B1 (en) 2020-05-13
US20230115170A1 (en) 2023-04-13
DK3097086T3 (en) 2018-02-05
NO2699580T3 (en) 2018-02-24
SI3323814T1 (en) 2020-10-30
HK1255870A1 (en) 2019-08-30
US11680049B2 (en) 2023-06-20
US11673871B2 (en) 2023-06-13
US10287258B2 (en) 2019-05-14
DOP2016000175A (en) 2016-08-15
US11655221B2 (en) 2023-05-23
AU2015208932B2 (en) 2017-02-16
IL246614B (en) 2018-02-28
AU2015208932A1 (en) 2016-07-28
ES2658516T3 (en) 2018-03-12
PE20161218A1 (en) 2016-11-27
PH12016501439B1 (en) 2017-02-06
HRP20180116T1 (en) 2018-03-23
US20230116721A1 (en) 2023-04-13
HK1225730B (en) 2017-09-15
US20230028726A1 (en) 2023-01-26
ES2808060T3 (en) 2021-02-25
WO2015110826A1 (en) 2015-07-30
US20200017455A1 (en) 2020-01-16
JP2017503832A (en) 2017-02-02
LT3097086T (en) 2018-02-26
US20230250071A1 (en) 2023-08-10
MX368840B (en) 2019-10-18
CN110483492A (en) 2019-11-22
IL252836A0 (en) 2017-08-31
MX2016009349A (en) 2016-10-13
CN105980367B (en) 2019-08-23
TW201612167A (en) 2016-04-01
KR20160111470A (en) 2016-09-26
AU2015208932A8 (en) 2017-03-09
JP7157791B2 (en) 2022-10-20
JP2022096662A (en) 2022-06-29
US20200247765A1 (en) 2020-08-06
JP7336563B2 (en) 2023-08-31
US20170057938A1 (en) 2017-03-02
CY1123391T1 (en) 2021-12-31
US11117874B2 (en) 2021-09-14
EA032794B1 (en) 2019-07-31
AU2018202956B2 (en) 2019-05-09
AU2015208932C1 (en) 2017-05-25
US20150210655A1 (en) 2015-07-30
JP2021046423A (en) 2021-03-25
DK3323814T3 (en) 2020-08-03
AU2018202956A1 (en) 2018-05-17
AU2017200338A1 (en) 2017-02-02
EP3744714A1 (en) 2020-12-02
AU2019202675A1 (en) 2019-05-16
US20230069044A1 (en) 2023-03-02
BR112016016224B1 (en) 2023-02-23
US20230062646A1 (en) 2023-03-02
CA2935625A1 (en) 2015-07-30
CN110483492B (en) 2023-07-21
AP2016009322A0 (en) 2016-07-31
US10669245B2 (en) 2020-06-02
HUE038274T2 (en) 2018-10-29
AU2019202675B2 (en) 2020-05-28
LT3323814T (en) 2020-10-26
CL2016001889A1 (en) 2016-12-09
PL3323814T3 (en) 2020-10-19
US20180251436A1 (en) 2018-09-06
US9815805B2 (en) 2017-11-14
TWI690517B (en) 2020-04-11
US20210238152A1 (en) 2021-08-05
US20230085620A1 (en) 2023-03-23
BR112016016224A2 (en) 2017-08-08
KR102417684B1 (en) 2022-07-05
IL265611A (en) 2019-05-30
EP3323814A1 (en) 2018-05-23
US20230025351A1 (en) 2023-01-26
US11667615B2 (en) 2023-06-06
CR20160327A (en) 2016-10-20
CA2935625C (en) 2022-10-18
US11655223B2 (en) 2023-05-23
MY194850A (en) 2022-12-19
US20230033573A1 (en) 2023-02-02
AU2015208932B8 (en) 2017-03-09
US9522894B2 (en) 2016-12-20
PT3323814T (en) 2020-08-05

Similar Documents

Publication Publication Date Title
HRP20201147T1 (en) (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors
MX2019005822A (en) Pyrrolopyrimidines as cftr potentiators.
NO20082000L (en) Pyrimidinamide Compounds as PGDS Inhibitors
HRP20171614T1 (en) Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
WO2009126530A3 (en) Piperidine derivatives as cgrp receptor antagonists
TN2012000139A1 (en) Cgrp receptor antagonists
CY1122121T1 (en) N-(5S,6S,9R)-5-AMINO-6-(2,3-DIPHTHOPHOPHAINYL)-6,7,8,9-TETPAHPO-5H-CYCLOHEPTA[B]PYRIDIN-9-YL-4-(2 -OXO-2, 3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-1-YL)PIPERIDINO-1-CARBOXYLATE SALT
AR086745A1 (en) 3,5-DIAMINO-6-CHLORINE-N- (N- (4- (4- (2- (HEXIL (2,3,4,5,6-PENTAHYDROXIHEXIL)) AMINO) ETOXI) PHENYL) BUTIL) CARBAMIMIDOIL) PIRAZINA -2-CARBOXAMIDE
TN2011000310A1 (en) Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd
CL2009000198A1 (en) Compounds derived from {2 '- [(n, n-disubstituted amino) -methyl] -biphenyl-3-yl} acetic acid, prostaglandin d2 mediators; pharmaceutical composition comprising them; and its use in the treatment of a respiratory, allergic or inflammatory disease, such as asthma, COPD or allergic rhinitis.
MY154895A (en) Pyrimidine hydrazide compounds as pgds inhibitors
WO2008057254A3 (en) Tricyclic compounds as matrix metalloproteinase inhibitors
AR080746A1 (en) (R) -N- (3- (7-METIL-1H-INDAZOL-5-IL) 1- (4- (1-METHYLPIPERIDIN-4-IL) PIPERAZIN-1-IL) -1-OXOPROPAN-2-IL ) -4- (2-OXO-1,2-DIHIDROQUINOLIN-3-IL) PIPERIDINE-1-CARBOXAMIDE ANTAGONIST RECEIVER CGRP.
UY32833A (en) DP2 ANTAGONISTS AND USES OF THE SAME
JP2009511591A5 (en)
AR078552A1 (en) PHENYLOXADIAZOL DERIVATIVES AS INHIBITING AGENTS OF THE PGDS
NZ591914A (en) Naphthylacetic acids
EA200900472A1 (en) PHOSPHODESTERASE INHIBITORS IV TYPE
MY142773A (en) Substituted 4-alkyl-and-alkanoyl-piperidine derivatives and their use as neurokinin antagonists
JP2016534088A5 (en)
RU2016102630A (en) INTEGRATED GRANULATED COMPOSITION WITH IMPROVED STABILITY, INCLUDING LEVOCETIRIZIN AND MONTELUKAST
RU2009134512A (en) HYDROCHLORIDE SALT 5- [3- (3-HYDROXYPHENOXY) AZETEDIN-1-IL] -5-METHYL-2,2-DIPHENYLHEXANAMIDE
NO20080457L (en) Chemical connections
CL2022003534A1 (en) Combination of alcaftadine and a corticosteroid
UY30935A1 (en) COMBINATION: -ANTAGONIST OF THE CHEMIOQUINE RECEIVER 1 (CCR1) -AGONIST OF THE GLUCOCORTICOID RECEPTOR- OPTIONALLY AGONIST B (BETA) 2, - PHARMACEUTICAL COMPOSITION CONTAINING IT - APPLICATIONS.